Who is a good candidate for GLP-1 therapy for weight loss
Referencias 1 Wu, G., Fang, Y.-Z., Yang, S., Lupton, J
Large clinical trials have generally not shown a major increase in depression across the broader population, but that doesnt mean rare or individual reactions cant happen
Orforglipron , an oral GLP-1 agonist, has shown the ability to maintain weight loss in patients switching from injectable therapies
Fourteen days of treadmill training significantly enhanced the expression of NRF2, GPX4, and SLC7A11 in the cerebral cortex of rats with cerebral ischemia-reperfusion injury